In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: The Chemours Company trades well below its high-confidence fair value estimate of $27.18, indicating significant potential upside amid a volatile range ($14.06–$123.90). Profitability and leverage scores are weak, increasing operational risk despite strong growth outlook and liquidity. Monte Carlo analysis shows no downside risk below the current price, highlighting asymmetrical opportunity versus risk.